MedTrace Logo

Progression of Hematopoietic Diseases in Shanghai, China

NCT00365014 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10757

Last updated 2013-07-23

No results posted yet for this study

Summary

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.

Conditions

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • University of Cincinnati

    collaborator OTHER

  • ExxonMobil Biomedical Sciences, Inc.

    collaborator INDUSTRY

  • British Petroleum P.L.C.

    collaborator INDUSTRY

  • Chevron Corporation

    collaborator INDUSTRY

  • ConocoPhillips

    collaborator INDUSTRY

  • Exxon Mobil

    collaborator INDUSTRY

  • Marathon Ashland

    collaborator UNKNOWN

  • Shell Chemicals

    collaborator INDUSTRY

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Richard D Irons, PhD · University of Colorado at Denver and Health Sciences Ctr.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00365014 on ClinicalTrials.gov